



NEW

**TO THE CASSS
FAMILY OF
MEETINGS**

September 26 – 28, 2011 • Hilton Rockville Hotel • Rockville, MD USA

1st International Symposium on the Higher Order Structure of Protein Therapeutics

Symposium Co-Chairs:

Wasfi Al-Azzam, *GlaxoSmithKline Pharmaceuticals*
John Dougherty, *Eli Lilly and Company*

Abstract Submission Deadline:

August 31, 2011 for Poster Consideration

Student Travel Grant Application Deadline:

July 15, 2011



CASSS

AN INTERNATIONAL SEPARATION SCIENCE SOCIETY

www.casss.org

1st International Symposium on the Higher Order Structure of Protein Therapeutics



This Symposium will include:

- Plenary Lectures
- Poster Sessions
- Technical (Vendor) Seminars
- Panel Discussions
- Exhibition
- Networking Opportunities

For More Information:

For program updates, hotel and registration information, abstract submission and information on the exhibition and/or sponsorship opportunities, please visit the Symposium Web site frequently at www.casss.org.

CASSS

5900 Hollis Street, Suite R3
Emeryville, CA 94608 USA
Phone: 510-428-0740
Fax: 510-428-0741
www.casss.org

Why Should You Attend This Meeting?

This meeting will gather academic, industrial and regulatory professionals as well as technology vendors at one time and place to discuss and advance a topic that is of interest to all. This meeting will use the long history of academic research and the industrial use of biophysical and HOS properties of protein therapeutics to assess the product quality of protein therapeutics. The involvement of global quality experts in this meeting will demonstrate the challenges that exist for considering protein therapeutic HOS as product quality and bringing them to the QC environment. In addition, sharing these discussions with regulatory agencies will not only make them aware of the challenges in the field but also benefit the audience in gauging regulatory expectations. Last but not least, the presence of various vendors of biophysical technologies help the audience advance their technologies to overcome challenges to meet industrial expectations specifically bringing those technologies to QC environments so that HOS of protein therapeutics can be considered as a quality attribute and may be easily monitored.

Academic, regulatory and industrial professionals from the following functions should plan to attend and engage in these important discussions:

- Discovery Sciences
- Process/Product Development
- Formulation Development
- Quality Assurance/Quality Control
- Regulatory Affairs
- Immunology
- Molecular and Cell Biology
- Analytical Development
- Manufacturing Sciences
- Clinical Pharmacology